Risk StewardRisk Steward
NOTES ON HEALTH, MONEY & A CHANGING WORLDPERSONAL PERSPECTIVES · MALAYSIA

A JOURNAL OF PERSPECTIVE

A changing world.
A judgement
of your own.

Progress gives us possibilities.
Perspective helps us choose.

Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.

TURN THE PERSPECTIVE

If we can detect more, what should we do differently?
Beh Risk Steward THE PERSON BEHIND THE PERSPECTIVE ↗

In focus

Fresh questions. Considered perspectives.

A NOTE FROM THE EDITOR

“I’m interested in a brighter future.
And the questions that help us prepare for it.”

Hope and preparation belong in the same conversation. This journal makes room for both.

A little more about Risk Steward ↗
Journal / Perspective

Health & Longevity

Could We Grow Older Without Growing Frailer?

What if growing older did not have to mean steadily losing the abilities we value?

That is the possibility that draws me to epigenetic reprogramming: research exploring whether some older or damaged cells can recover more youthful function.

Older adult beside a book and reading glasses in soft daylight
AI-generated editorial illustration.

A small trial with a bigger question

ER-100 is an experimental gene therapy from Life Biosciences, a company co-founded by Harvard geneticist David Sinclair. It uses controlled activity of three factors—OCT4, SOX2 and KLF4—to try to reset aspects of how cells use their genetic instructions. The aim is partial reprogramming, rather than turning mature cells completely back into stem cells. [1]

An important foundation was a 2020 study from Sinclair and colleagues, which reported improved vision and regeneration in mouse experiments. Those findings were in mice; they did not establish that people could live longer. [2]

Now, ER-100 is being studied in people with optic nerve conditions, including glaucoma. On 8 October 2026, Life Biosciences reported that the first three glaucoma participants tolerated treatment through 56 days, with preliminary visual-field improvements in two. [3]

These encouraging findings were company-reported interim observations from a tiny, open-label safety study without a randomized control group. They do not prove that aging has been reversed in people, that blindness has been cured, or that lifespan has increased. Sinclair’s role in the company also matters when interpreting its announcements. [3] [4]

My view: more healthy years would change everything

What more healthy years could mean

Seeing clearly. Staying active. More time with people we love.

More birthdays would be welcome. More healthy birthdays would be even better.

This connects with longevity escape velocity (LEV): the hypothetical point at which successive medical advances extend remaining life expectancy faster than time passes. It is an idea about sustained future progress, not an achievement demonstrated by ER-100. [5]

We do not know whether—or when—we will reach it. I see two separate uncertainties: how long we might live, and how much of that time we could remain independent. A treatment that improves one aspect of health would not settle either question for our whole lives.

Rather than choosing a single prediction, I would test two possibilities: more healthy years, and more years needing support. Would our income, care arrangements and family responsibilities remain workable in each? That lets us welcome progress without making our plans depend on a breakthrough arriving on time.

If science gives us more good years, I would rather the retirement fund did not retire before we do.

Research checked: 1 November 2026. General education and personal commentary, not medical advice. ER-100 remains investigational; permission to conduct a trial is not approval for routine treatment.

References

[1] Life Biosciences: ER-100 trial clearance and background

[2] Lu et al., Nature (2020): Reprogramming to recover youthful epigenetic information and restore vision

[3] Life Biosciences: Interim Phase 1 observations, 8 October 2026

[4] ClinicalTrials.gov: ER-100 study NCT07290244

[5] Aubrey de Grey, PLOS Biology (2004): Escape Velocity

A QUESTION TO CARRY FORWARD

Original article ↗